USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Medimmune Limited

USPTO PatentsView assignee record - 327 granted patents across 28 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

327

Total patents granted

CPC technology areas

17.4

Avg claims per patent

-2%

5-year filing velocity

The verdict

Medimmune holds 327 US patents across 28 technology areas, rank #1,293 of 50,000 tracked assignees.

#1,293
of 50,000 US assignees by volume: Top 8%
by Innovation Score (54.1/100): 17.4
avg claims per patent: -2%
filing velocity, last 5 yrs

Portfolio overview

Medimmune Limited has been granted 327 US utility patents between 2015 and 2025, placing Medimmune Limited at rank #1,293 across all assignees tracked by PlainPatent. This portfolio spans 28 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.4 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Medimmune Limited is one of the more focused assignees in the PatentsView dataset. By volume, Medimmune sits between Yissum Research Development Company OF THE Hebrew University OF Jerusalem Ltd. (329 patents, rank #1,289) and Klemm + SOHN Gmbh & Co. KG (326 patents, rank #1,297) - the closest US assignees by grant volume. The composite Innovation Score of 54.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 162 grants, compared with 165 in the 2015–2019 window, a -2% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Medimmune Limited's 17.4 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 28 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Medimmune Limited against peers pursuing similar technology classes.

Yissum Research D…

329
Safran

328
Alpha and Omega S…

327
Brother Industries

327
University of Hou…

327
Medimmune ◀

327
Bayer Pharma Akti…

326
Hangzhou Hikvisio…

326
Klemm + SOHN & KG

326

What this shows Medimmune holds 327 patents at rank #1,293, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Medimmune

By rank, the assignees closest to #1,293 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Medimmune's primary technology class.

Medimmune's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

54 Top 8% higher than 92% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Medimmune Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	27	8.3%
2016	31	9.5%
2017	29	8.9%
2018	45	13.8%
2019	33	10.1%
2020	44	13.5%
2021	28	8.6%
2022	26	8.0%
2023	33	10.1%
2024	18	5.5%
2025	13	4.0%

Which technologies does Medimmune Limited patent most?

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 283

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 280

C07K - PEPTIDES 264

C07D - HETEROCYCLIC COMPOUNDS 57

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 52

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 47

C12P - FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 16

Y02A - TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE 16

Y02P - CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS 13

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 8

C12Y - ENZYMES 6

C07C - ACYCLIC OR CARBOCYCLIC COMPOUNDS 6

C07H - SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 5

B01D - SEPARATION 5

G16H - HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA 5

Top 15 of 28 technology areas

Patent Moat Analysis

Portfolio Volume Moderate

Tech Breadth Multi-domain

Claim Depth Standard

Velocity Declining

Where it ranks

Overall rank by patents

#1,293

Across all tracked assignees

Innovation Score

54.1 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Medimmune Limited hold?

Medimmune Limited holds 327 US granted patents filed between 2015 and 2025, spanning 28 technology areas.

What is Medimmune Limited's Innovation Score?

Medimmune Limited has an Innovation Score of 54.1 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Medimmune Limited focus on?

Medimmune Limited's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 283 patents. The company has filed patents in 28 CPC subclasses total.

Is Medimmune Limited's patent filing rate increasing or decreasing?

Medimmune Limited's recent filing velocity is -2% compared to the prior five-year period. Filing activity has slowed relative to earlier years.

What does claim depth mean for Medimmune Limited's patents?

Medimmune Limited's patents average 17.4 claims each. This falls within the standard range, providing solid legal coverage.

How is the Medimmune Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Medimmune's 327 grants land it in the top 8% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Medimmune ranks #1,293 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.